Table 1 Prognostic clinical features of ALL
From: Novel agents and biomarkers for acute lymphoid leukemia
Risk factors | Prognosis association |
|---|---|
At presentation | |
  Age | Adverse outcome with advancing age |
  CNS involvement | Adverse outcome |
  Presenting WBC count | Adverse for B-ALL > 30 |
| Â | Adverse for T-ALL >100 |
  ECOG PS | Poor PS at diagnosis were an independent predictor of inferior outcomes |
  Cytogenetics | Favorable: hyperdiploidy |
Adverse: t(9;22), t(4;11), t(8;14), complex (≥ 5 abnormalities), hypodiploidy, triploidy, -7, del(7p), +8, MLL translocations, t(1;19), t(17;19), t(5;14)] | |
In response to therapy | |
  Time to initial response | Adverse: failure to attain complete remission within 4 weeks of induction |
  Detection of MRD | Adverse: detection at various time-specific points in several studies |